baber/WOPTO huggingface dataset:
Patent JP-2752202-B2 (JP)
IPC: B65B51/32
Filed: 1989-12-14
Granted: 1998-05-18
Abstract: The device comprises a support plate (10) mounted on a first cylindrical body (13) and moved by a first system and a heating body (16) surrounding the said cylindrical body under the support plate and an insulating body (20) surrounding the heating body and integral therewith mounted on a second cylindrical body and moved coaxially with respect to the first cylindrical body by a second system, the first system forming an integral part of the heating body, of the insulating body and of the second cylindrical body. 
<IMAGE>
Patent JP-H06102763-B2 (JP)
IPC: C09D5/44
Filed: 1987-11-16
Abstract: PCT No. PCT/EP87/00713 Sec. 371 Date Nov. 20, 1989 Sec. 102(e) Date Nov. 20, 1989 PCT Filed Nov. 16, 1987 PCT Pub. No. WO88/03941 PCT Pub. Date Jun. 2, 1988.The invention relates to cathodic water-dilutable binders which contain primary amino groups neutralized with acids and introduced via ketimine groups. The binders have been prepared by reacting (A) a synthetic resin containing epoxy groups with (B) at least one compound which, in addition to a mercapto group which is reactive toward epoxy groups, also possesses at least one ketimine group, and, if required, (C) other modifying compounds, such as, for example, monocarboxylic acids and/or other primary and/or secondary amines, and have then been neutralized with an acid.
Patent JP-3091224-B2 (JP)
IPC: B29C70/66
Filed: 1992-06-12
Granted: 2000-09-25
Abstract: A composite material comprises a web shaped material which is impregnated with a curable resin and which contains thermoplastic particles distributed in the web shaped material. The thermoplastic particles are of an expandable type but occur in the composite material in substantially unexpanded form. The curable resin is in a A- or B-stage. In addition, the invention comprises use of a composite material of this nature for producing laminates by warm pressing and a method for producing the composite material.
Patent JP-2870657-B2 (JP)
IPC: A61K9/50
Filed: 1988-11-18
Granted: 1999-03-17
Abstract: Novel liposome-entrapped cationic, lipophilic drug compositions, e.g., anthracycline antineoplastic agent compositions, and multistep entrapment/loading procedures for preparing them are disclosed. These procedures involve forming liposomes from phospholipids, such as distearoyl phosphatidyl-choline or a similar long chain fatty acid diester phospholipid, to be loaded with the drug, e.g., daunorubicin or doxorubicin, in aqueous medium in the presence of an acid, e.g., an organic acid which can be a monofunctional pyranosidyl acid such as lactobionic acid, adding the drug, and then adding a base such as calcium carbonate whose cations cannot pass through the vesicles' bilayers to charge neutralize the organic acid anions in the external aqueous phase and induce the acid anions in the internal aqueous phase to become charge neutralized by attracting the cationic, lipophilic drug.
Patent JP-3504667-B2 (JP)
IPC: A01N53/00
Filed: 1995-05-22
Granted: 2004-03-08
Abstract: Methods of inhibiting an ethylene response in a plant, inhibiting abscission in a plant or prolonging the life of a cut flower, comprise application of a cyclopropene deriv. of formula (I), a 1,1,1-propellane deriv. of formula (II), or a cpd. isolated from diazocyclopentadiene (DCPD) irradiation by gas chromatography (gc) by elution at about 0.7 min. from a 23% SP-1700 on 80/100 Chromosorb P AW (RTM) glass column: m = 1 or 2; n = 1-3; and R = H, 1-4C satd. or unsatd. alkyl, OH, halo, alkoxy, amino, or carboxy. When the ethylene response is fruit and vegetable ripening, the fruit and vegetables are tomatoes, apples, pears, bananas, papaya, mangoes, peaches, apricots, nectarines, kiwi, pineapple, persimmon, avocadoes, melons, berries, genus Cucumis, green beans, lima beans, lettuce, spinach, cabbage, potatoes, carrots, onions, basil, oregano, dill, soybean, peas, corn, broccoli, cauliflower, and asparagus. When the ethylene response is flower senescence, the flowers are azalea, hydrangea, hibiscus, antirrhinum, poinsettia, cactus, begonia, rose, tulip, daffodil, petunia, carnation, lily, gladiolus, alstromeria, anemone, columbine, avalia, aster, bougainvillea, camellia, bell flower, cockscomb, false cypress, chrysanthemum, clematis, cyclamen, freesia, and orchid. Plants involved in the inhibition of abscission are cotton, apple, pear, cherry, pecan, grape, olive, coffee, snapbean, weeping fig, dormant seedlings, privet, photinea, holly, ferns, schefflera, aglaonema, cotoneaster, etc.
Patent JP-2843921-B2 (JP)
IPC: A61P29/00
Filed: 1994-07-05
Granted: 1999-01-06
Abstract: PCT No. PCT/JP94/01092 Sec. 371 Date Mar. 3, 1996 Sec. 102(e) Date Mar. 3, 1996 PCT Filed Jul. 5, 1994 PCT Pub. No. WO95/02595 PCT Pub. Date Jan. 26, 1995A compound of chemical formula (I) and its pharmaceutically acceptable salt:    <IMAGE>  (I)  wherein X and Y are each hydrogen, halogen, C1-C6alkyl, halosubstituted C1-C6alkyl, C1-C6alkoxy, C1-C6alkylthio, C1-C6alkylsulfinyl, C1-C6alkylsulfonyl, or tri(C1-C6alkyl)silyl; Ar1 and Ar2 are each independently aryl or heteroaryl, optionally substituted by halogen; A is -CO- or -(CH2)-; Z-A- is at the 2 or 3 position on the quinuclidine ring; and Z is -OH, C1-C6alkoxy, NR1R2 or the like. Representative compounds are (3S,4R,5S,6S)-5-[3,5-bis(trifluoromethyl)-benzyloxy]-N,N-dimethyl-6-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-carboxamide, and -3-carboxylic acid. These novel benzyloxyquinuclidines are active as substance P receptor antagonists and are thus useful for treating gastrointestinal disorders, central nervous system disorders, allergy, inflammatory diseases, asthma, pain, emesis, migraine, urinary incontinence, or angiogenesis in mammals, especially humans.
Patent JP-3622982-B2 (JP)
IPC: H04H20/88
Filed: 1997-06-03
Granted: 2005-02-23
Abstract: A method of coding stereo audio spectral values first carries out grouping of those values in scale factor bands, with which scale factors are associated. Sections are formed next, each comprising at least one scale factor band. The spectral values are coded within at least one section with a code book assigned to the section, out of a plurality of code books each with a code book number assigned to it, the number of the code book used being transmitted as side information to the coded stereo audio spectral values. At least one additional code book number is provided, which does not refer to a code book but shows information relevant to the section to which it is assigned. A method of decoding stereo audio spectral values which are partly coded by the intensity stereo process and which have side information uses the relevant information, showing the additional code book numbers, to cancel the existing coding of the stereo audio spectral values.
Patent JP-3881020-B2 (JP)
IPC: H01L21/8247
Filed: 1996-06-14
Granted: 2007-02-14
Abstract: A bidirectional passgate switch for connecting two conductors utilizes technology such as electrically erasable programmable read only memory (EEPROM). The switch includes two EEPROM components wherein the floating gates of the components are shared. In one embodiment a first n-channel passgate transistor is used for programming and storage of the state of the switch. The oxide of the first transistor is a thin oxide to enable ease of programming. A second n-channel passgate transistor functions as the bidirectional switch wherein the source and drain terminals are coupled to the routing lines to be selectively connected. The second transistor oxide is a thick oxide to minimize the leakage due to tunneling. Thus, the programming lines and routing lines are separated, making the programming process simpler while minimizing leakage. <IMAGE>
Patent JP-H0722753-B2 (JP)
IPC: C02F9/00
Filed: 1990-06-13
Abstract: PCT No. PCT/DE90/00446 Sec. 371 Date Dec. 13, 1991 Sec. 102(e) Date Dec. 13, 1991 PCT Filed Jun. 13, 1990 PCT Pub. No. WO90/15778 PCT Pub. Date Dec. 27, 1990.A process and an installation for treating liquids, which are charged with pollutants that are difficult to break down, by means of wet oxidation with ozone-containing gas and UV radiation. The installation comprises injectors by means of which ozone-containing gas produced in an ozone generator can be passed into the liquid. The liquid is then introduced into a reaction and degasification vessel, before it passes through the UV irradiation units.
Patent JP-3304091-B2 (JP)
IPC: G06F3/023
Filed: 1994-08-31
Granted: 2002-07-22
Abstract: Input apparatus scaled for non-adult humans and adult humans having small hands. The input apparatus are especially well suited for use as computer keyboards for use by schoolchildren. Also disclosed is a computing system including the input apparatus.
Patent JP-3647451-B2 (JP)
IPC: C07D245/06
Filed: 1994-09-22
Granted: 2005-05-11
Abstract: A benzolactam derivative represented by the following formula (I):   <CHEM> wherein n represents an integer of from 1 to 3; R<1> represents a straight- or branched-chain alkyl group or an aralkyl group; R<2> represents a straight- or branched-chain alkyl group; R<3> and R<4> independently represent a hydrogen atom or a straight- or branched-chain alkyl group, and when R<3> and R<4> are adjacent each other on the phenyl group, they may be combined to form a cycloalkyl ring together with two carbon atoms of the phenyl group to which R<3> and R<4> bind, and said cycloalkyl ring may optionally have one or more substituents; and a anti-retroviral agent comprising the same as an active ingredient.
Patent JP-3212996-B2 (JP)
IPC: G01N21/55
Filed: 1991-06-06
Granted: 2001-09-25
Abstract: The concentration of a substance, especially glucose, in the blood is measured in vivo by applying to the skin two wavelengths of infrared light and measuring the difference in the absorption of the two wavelengths, preferably in the range of 3-10  mu m, one being a sample wavelength at which the substance shows a specific absorption and the other being a reference wavelength at which the substance shows no specific absorption. Simultaneously the concentrations of interfering components are measured in the same way and the result for the substance is corrected with regard to the measured concentrations of interfering components. Infrared light is transmitted through optical fibres (10, 10a) to a detector having two chambers (15, 15a), a sample wavelength to one chamber (15) and a reference wavelength to the other (15a), and a transducer (14) between the chambers measures the difference in the pressures induced in the respective chambers when the tissue beneath the chambers is heated by absorption of the infrared light transmitted to it.
Patent JP-3542136-B2 (JP)
IPC: H04R1/00
Filed: 1996-09-02
Granted: 2004-07-14
Abstract: An inertial vibration transducer (9) characterised by a motor coil assembly comprising a tubular member (18) and a coil (13) rigidly fixed to the tubular member, and by a magnet assembly (15) disposed concentrically within the motor coil, and resilient means (19) supporting the magnet assembly for axial movement relative to the motor coil, the motor coil and tubular member being adapted to be rigidly mounted to a distributed mode radiator (2).
Patent JP-3310283-B2 (JP)
IPC: C12N15/54
Filed: 1991-06-03
Granted: 2002-08-05
Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity. These methods may be extremely useful in screening compounds for the presence of a desired cellular factor activity. In specific embodiments, compounds which may be useful in the treatment of Alzheimer's disease, peripheral neuropathies, and diabetes may be identified using the methods of the invention.
Patent JP-3676804-B2 (JP)
IPC: D02G3/40
Filed: 1993-02-11
Granted: 2005-07-27
Abstract: An abrasive filament, including a thermoplastic elastomer having abrasive particles dispersed and adhered therein, exhibits improved life over previously known abrasive-filled polymeric filaments. Methods of making abrasive filaments of the invention, articles including the abrasive filaments, and methods of abrading surfaces using the abrasive articles of the invention are also described.
Patent JP-3625825-B2 (JP)
IPC: A61K31/135
Filed: 1994-03-24
Granted: 2005-03-02
Abstract: PCT No. PCT/EP94/00949 Sec. 371 Date Oct. 3, 1995 Sec. 102(e) Date Oct. 3, 1995 PCT Filed Mar. 24, 1994 PCT Pub. No. WO94/22434 PCT Pub. Date Oct. 3, 1994A cylindrical delayed release tablet with a convex or flat upper side and lower side is provided, along with a method for its production and a gelatin capsule containing 3-200 tablets of the same having identical or different release rates, wherein the tablet if made of  beta -phenylpropiophenone derivatives of the formula I as active ingredient    <IMAGE>  I  where R is n-propyl or 1,1-dimethylpropyl, and their pharmacologically acceptable salts, wherein the tablet has a height and diameter that are both, independently of one another, 1-3 mm, the active ingredient content is in the range from 81-99.9% of the weight of the microtablet, (but not taking into account the weight of any coating which is present, the active ingredient density is greater than 1, the release of active ingredient in the USP paddle method at 50 rpm is 80% as a maximum after 3 hours and as a minimum after 24 hours, the release rate is virtually independent of the pressure when compressing the tablets, and the tablet contains no release-delaying ancillary substance but can contain 0.1-5% by weight of a lubricant and 0-18.9% by weight of other conventional ancillary substances.
Patent JP-3750819-B2 (JP)
IPC: A61P7/00
Filed: 1993-04-16
Granted: 2006-03-01
Abstract: A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.
Patent JP-4206133-B2 (JP)
IPC: C07K16/08
Filed: 1997-12-03
Granted: 2009-01-07
Abstract: The invention relates to a method of screening for precursor lesions which can lead to cervical malignancy, methods of detecting and typing human papilloma virus infections, and reagents of use in these methods.
Patent JP-4023826-B2 (JP)
IPC: A61B5/097
Filed: 1997-02-11
Granted: 2007-12-19
Abstract: In the treatment of obstructive sleep apnea, a method and apparatus are disclosed for detecting obstructive apnea and optimizing the controlled positive pressure to minimize the flow of air from a flow generator while still ensuring that flow limitation in the patient's airway does not occur. In particular, the invention relates to a breathing device and method of use to adjust a controlled positive pressure to the airway of a patient by detecting flow limitation from analysis of an inspiratory flow waveform. Once the presence of flow limitation has been analyzed, the system determines an action to take for adjustment of the controlled positive pressure. The pressure setting is raised, lowered or maintained depending on whether flow limitation has been detected and on the previous actions taken by the system. The preferred breathing apparatus consists of a flow generator, a flow sensor, an analog to digital converter, a microprocessor, and a pressure controller, a patient supply hose, a nasal fitting, and, optionally, a pressure transducer. Using the method of the present invention, the microprocessor adjusts the air pressure in the patient supply hose when flow limitation is detected in the airway of the patient.
Patent JP-3735821-B2 (JP)
IPC: A61B17/00
Filed: 1996-03-07
Granted: 2006-01-18
Abstract: PCT No. PCT/CH96/00086 Sec. 371 Date Sep. 29, 1997 Sec. 102(e) Date Sep. 29, 1997 PCT Filed Mar. 7, 1996 PCT Pub. No. WO96/29942 PCT Pub. Date Oct. 3, 1996The catheter connected to a rotary drive mechanism has, at its front end, a cutting tool which consists of a stator and rotor. Cutting edges arranged on the circumference of the rotor and stator interact in a shearing action. The detached deposits are conveyed through a tubular sheath and into a collection container via a discharge chamber. A drive shaft which is arranged inside the tubular sheath, and which connects the rotary drive mechanism to the rotor, is designed as a conveyor screw and is used for the conveying. A rotary catheter of this kind is used for carefully removing and withdrawing blood clots and stenoses from narrowed blood.
Patent JP-3503900-B2 (JP)
IPC: A01G5/04
Filed: 1996-05-23
Granted: 2004-03-08
Abstract: The holder consists of a cone made from a folded semi-circle of material, with a tab (3) and slits (4) to adjust its size, and opening vanes (11) at the top to make a hole through which the stems of a bouquet of flowers can be inserted. The holder can be held in shape with a ribbon threaded through holes (6) near its upper end, and a sheet (8) of wrapping paper can be used to cover the base and sides of the cone for presentation.  Variants of the design, either conical in cylindrical in shape, can be made with a base to hold a small amount of water which keeps the flowers fresh, e.g. as a temporary vase, or for transport.
Patent JP-4148994-B2 (JP)
IPC: A61K38/00
Filed: 1997-04-11
Granted: 2008-09-10
Abstract: Analogs of glucagon-like peptide-2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their preparation by synthesis is described.
Patent JP-3181298-B2 (JP)
IPC: A61F2/60
Filed: 1998-03-04
Granted: 2001-07-03
Abstract: Disclosed is a damping device for a leg prosthesis, comprising a tubular casing consisting of an outer sleeve (5) with a bottom (7) on one end and another open end, and an inner sleeve (6) which can slide backwards and forwards in an axial direction. A pressure spring (12) is arranged on the inside between both sleeves. Both sleeves can move between an expanded position and a retracted position. The pressure spring (12) is chosen in such a way that it exhibits a pre-determined initial tension even in an expanded position.
Patent ES-2322685-B2 (ES)
Title: Utilizacion de dosis bajas de igf-ii en el envejecimiento por sus efectos neuroprotectores y hepatoprotectores.
Inventor: CASTILLA DE CORTAZAR M INMACULADA
IPC: A61K38/30
Filed: 2006-11-21
Granted: 2010-03-15
Abstract: Utilización de dosis bajas de
IGF-II en el envejecimiento por sus efectos 
neuroprotectores y hepatoprotectores. 
     La presente invención se refiere a la
administración de IGF-II en dosis  bajas en el
envejecimiento por sus efectos neuroprotectores y hepatoprotectores,
 y concretamente a su uso en la elaboración de medicamentos o
composiciones  farmacéuticas con efecto neuroprotector y
hepatoprotector. En particular,  la aplicación de la presente
invención se refiere a mamíferos, incluyendo  obviamente al ser
humano. El tratamiento sustitutivo o compensatorio con 
IGF-II normaliza la glucemia, disminuye los niveles
de triglicéridos y  de colesterol, sin modificar las concentraciones
plasmáticas de IGF-I y  de testosterona. En resumen,
la administración de IGF-II, a dosis bajas,  induce
efectos antioxidantes, neuroprotectores y hepatoprotectores,
mejorando  la función mitocondrial.
Patent AU-2001258388-B2 (AU)
Title: Method for producing textile products, in particular tufted products, provided with geometrical designs or not and resulting products
Inventor: LALONDE GERARD
IPC: D06P3/82
Filed: 2001-04-19
Granted: 2006-05-04
Abstract: To produce a material with a patterning of a geometric or non-geometric design, it incorporates at least two yarns in a uniform and repeated structure. A given pattern is laid of dye pastes in different colors with a particular affinity for each specific type of yarn. The fabric is produced on a tufting machine, using two bars or more with a relative longitudinal displacement between them. The tufted loops are of the same or different height levels, using the different yarn feeds. The tufted material is stabilized by a conventional coating, and is cut into tiles. The tiles are gathered by an index system at an assembly where dye pastes are applied in an accurate repeat color pattern, using an injection action to deliver the dyes of different colors into accurate locations on to the material surface and into its body mass.
Patent AU-2001287931-B2 (AU)
Title: Secure delivery apparatus
Inventor: SWIFT NICHOLAS
IPC: A47G29/22
Filed: 2001-09-24
Granted: 2004-05-20
Abstract: Security apparatus ( 10 ) for the secure receipt and retention of articles ( 30 ) delivered thereto. The security apparatus ( 10 ) comprises a housing ( 12 ) having an upper chamber ( 14 ) and a lower chamber ( 16 ) separated from one another by a movable partition ( 15 ). The upper chamber ( 14 ) has an entrance opening ( 18 ) for the passage therethrough of a product ( 30 ) to be delivered to the apparatus ( 10 ) and a pivoted closure member ( 20 ) for said entrance opening ( 18 ). The movable partition ( 15 ) is slidable inwardly and outwardly of the apparatus ( 10 ) between respectively a closing position in which it separates the upper and lower chambers ( 14,16 ) from one another and an open position in which it permits inter-communication between the upper and lower chambers ( 14,16 ). Interaction means ( 25 ) are provided between the partition ( 15 ) and said closure member ( 20 ) whereby the closure member ( 20 ) can only be moved to open said entrance opening ( 18 ) when the partition ( 15 ) is in said closing position.
Patent AU-2002228752-B2 (AU)
Title: Remote network management software
Inventor: HAGER GEOFFREY
IPC: G06F15/173
Filed: 2001-10-26
Granted: 2006-03-02
Abstract: A system and method is provided for remote administration and management of a computer network, by installation of distributed software agents in remote network components, such as software agents implemented using encapsulated reusable interfaces such as COM or CORBA interfaces. Remote network management is effected by communication with the distributed agents using a structured language-independent parsable text document, such as a markup language; e.g. XML.